AAV One-Vector System for Continuous Dopamine Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment strategies for Parkinson's disease, particularly the use of L-DOPA, lead to diminishing efficacy and severe side effects like dyskinesias due to intermittent dopamine delivery, and existing gene therapy approaches struggle to control the expression ratio of enzymes involved in dopamine production.
Innovation Solution
A novel one-vector expression system using an adeno-associated vector (AAV) that differentially expresses tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1) with a Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) and Synapsin1 promoters, optimizing the stoichiometric ratio for continuous dopamine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L-DOPA is administered orally to treat Parkinson's disease, then dopamine deficiency is compensated, but intermittent dopamine delivery causes dyskinesias and diminishing treatment efficacy
Solution Approach 1:
The patent implements continuous dopamine production by delivering genes encoding dopamine-synthesizing enzymes (TH, GCH1, AADC) that continuously produce dopamine within the brain, replacing the intermittent oral L-DOPA administration with a continuous endogenous production system
Solution Approach 2:
The patent uses viral vectors as intermediaries to deliver therapeutic genes to target cells in the brain, enabling local dopamine production without requiring repeated oral administration of L-DOPA
2Ease of manufacture
If multiple separate AAV vectors are used to deliver TH and GCH1 genes, then gene delivery is achieved, but control over expression ratio between enzymes is lost
Solution Approach 1:
The patent merges multiple gene delivery functions into a single AAV vector that simultaneously delivers TH, GCH1, and AADC genes, ensuring co-delivery to the same target cells and enabling precise control over the stoichiometric expression ratios of all enzymes
Solution Approach 2:
The patent optimizes expression ratios by adjusting promoter strength, gene copy number, and transduction conditions to achieve the desired stoichiometric balance between TH, GCH1, and AADC enzymes within a single vector system
3Stability of the object's composition
If enzyme replacement strategy is implemented to provide continuous L-DOPA production, then dopamine deficiency is addressed, but localization and expression control of enzymes remain challenging
Solution Approach 1:
The patent combines multiple enzyme-encoding genes (TH, GCH1, AADC) with their respective regulatory elements into a single integrated viral vector construct, simplifying delivery while maintaining controlled localization and expression
Solution Approach 2:
The patent uses neuron-specific promoters (Synapsin1, TH promoter) to restrict enzyme expression to dopaminergic neurons and their projection targets, ensuring local dopamine production precisely where needed in the brain
Data Source
Figure 1
Figure 2
Figure 3A~3D
AI summary
The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP- cyclohydrolase 1 (GCH1 ). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.